ลูเซียส เอลาฟิบรานอร์ – สั่งซื้อออนไลน์

EUR 823.33

2,900+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

Elafibranor received accelerated approval in the United States in June 2024.

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
80mg*30 comprimes
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

10000 en stock

Informations produit

Nom anglais
Elafibranor
Nom générique
Elafibranor

Caractéristiques

Spécification
80mg*30 comprimes
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Indications

Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.

Mécanisme d’action

Elafibranor Mecanisme d action Mecanisme d action ,

Posologie

2 , , / (2.1) 80 mg, (2.2) 2.1 IQIRVO IQIRVO [ Precautions (5.1)] IQIRVO , [ Precautions (5.3), (8.1, 8.3)] 2.2 IQIRVO 80 mg, [ (12.3)] 2.3 IQIRVO 4 4 , [ (7.2)]

Precautions

5 Precautions IQIRVO , (CPK) , IQIRVO 5.1 IQIRVO , 5.2

Package Insert

Ingredients

11 GFT1007 PPAR pH 1.2 6.8 , pH 7.5 , DMSO , C₂₂H₂₄O₄S, 384.49 g/mol, 2-(2,6- -4-{3-[4-( ) ]-3- -1- -1- } )-2- , IQIRVO 80 mg ,

Indications

Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.

Posologie

2 , , / (2.1) 80 mg, (2.2) 2.1 IQIRVO IQIRVO [ Precautions (5.1)] IQIRVO , [ Precautions (5.3), (8.1, 8.3)] 2.2 IQIRVO 80 mg, [ (12.3)] 2.3 IQIRVO 4 4 , [ (7.2)]

Precautions

5 Precautions IQIRVO , (CPK) , IQIRVO 5.1 IQIRVO , 5.2

Use in Pregnancy and Lactation

8.1 , IQIRVO , elafibranor , / , IQIRVO ,

Clinical Pharmacology

12 12.1 Mecanisme d action GFT1007 PPAR , PPAR-α PPAR-γ PPAR-δ , PBC PPAR-α PPAR-δ ,PPAR-δ 21 FGF21 CYP7A1 ,CYP7A1 PPAR ,elafibranor GFT1007 PPAR-α EC50 46 nM 14 nM,Em 0.05 0.05

Pharmacology and Toxicology

13 13.1 2 CD-1 , elafibranor 1 3 10 30 mg/kg/ , elafibranor GFT1007 AUC, 0.007 0.14 0.003 0.16 Sprague-Dawley , elafibranor 10 mg/kg/ elafibranor GFT1007 AUC 0.36 , 30 mg/kg/ elafibranor GFT1007 AUC 2.1 ,elafibranor

Clinical Studies

14 1 (NCT04526665) IQIRVO 161 (UDCA) (PBC) IQIRVO 80 mg (n=108) (n=53), , 52 , UDCA (ALP) ≥ (ULN) 1.67 , (TB) ≤ 2

Avis produit (13)

Filtre : Tous les avis
4.8★★★★★
13 avis clients10 achats verifies
+o***e· 3周前
★★★★
+t***3· 1个月前
Achat verifie
★★★★★

Description

Indications

Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.

Mécanisme d’action

Elafibranor Mecanisme d action Mecanisme d action ,

Posologie

2 , , / (2.1) 80 mg, (2.2) 2.1 IQIRVO IQIRVO [ Precautions (5.1)] IQIRVO , [ Precautions (5.3), (8.1, 8.3)] 2.2 IQIRVO 80 mg, [ (12.3)] 2.3 IQIRVO 4 4 , [ (7.2)]

Precautions

5 Precautions IQIRVO , (CPK) , IQIRVO 5.1 IQIRVO , 5.2